Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new estrogen option for menopause may be on the horizon. A pooled phase 3 analysis found that estetrol (E4) — a naturally occurring fetal estrogen — significantly reduced the frequency and severity of hot flashes at both 15 mg and 20 mg doses compared to placebo. Benefits appeared as early as week 4, with the 20 mg dose showing greater reductions. A standalone FDA decision is expected by Q3 2027.
A new estrogen option for menopause may be on the horizon
Estetrol (E4), a native estrogen produced only by the fetal liver, is showing real promise for menopausal hot flashes. A post hoc pooled analysis of two phase 3 trials — E4COMFORT I and II — presented at The Menopause Society 2026 Annual Meeting found that both 15 mg and 20 mg daily oral doses significantly reduced the frequency and severity of moderate-to-severe vasomotor symptoms (VMS) compared to placebo in postmenopausal women.
Improvements kicked in by week 4 and grew through week 12, with the 20 mg dose consistently outperforming the 15 mg dose. E4 works by activating estrogen receptors in the cell nucleus while blocking membrane receptors — a mechanism that may mean fewer risks around blood clotting and breast tissue than traditional estrogens.
By the Numbers
Why it matters: A standalone E4 pill is currently under FDA review, with a decision expected by Q3 2027. If approved, it could give clinicians a new hormonal option with a potentially safer cardiovascular and breast profile — expanding personalized treatment choices for the millions of women managing menopausal symptoms.
